Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

@article{Korpanty2010AntiangiogenicTI,
  title={Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.},
  author={Grzegorz J. Korpanty and Elizabeth Smyth and Laura A. Sullivan and Rolf A Brekken and Desmond N. Carney},
  journal={Experimental biology and medicine},
  year={2010},
  volume={235 1},
  pages={3-9}
}
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments

C Gridelli
Oncologist, • 2007
View 3 Excerpts
Highly Influenced

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

The New England journal of medicine • 2006
View 3 Excerpts
Highly Influenced

Biological mechanisms of bevacizumab-associated adverse events.

Expert review of anticancer therapy • 2009
View 1 Excerpt

Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2008
View 1 Excerpt

Pinedo , Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

X. Zhu
Nat Rev Cancer • 2007

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…